Compare MCB & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCB | OPK |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2017 | 2011 |
| Metric | MCB | OPK |
|---|---|---|
| Price | $91.94 | $1.48 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $98.67 | $1.60 |
| AVG Volume (30 Days) | 108.6K | ★ 4.4M |
| Earning Date | 04-21-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 11.64 | N/A |
| EPS | ★ 4.40 | N/A |
| Revenue | $11,053,000.00 | ★ $606,879,000.00 |
| Revenue This Year | $37.22 | N/A |
| Revenue Next Year | $14.75 | $4.24 |
| P/E Ratio | $20.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $64.66 | $0.98 |
| 52 Week High | $102.04 | $1.73 |
| Indicator | MCB | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 41.38 | 62.98 |
| Support Level | $91.19 | $1.25 |
| Resistance Level | $93.56 | $1.58 |
| Average True Range (ATR) | 1.85 | 0.06 |
| MACD | -0.11 | 0.02 |
| Stochastic Oscillator | 17.31 | 93.87 |
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.